Zolgensma, a Treatment for Spinal Muscular Atrophy, Takes One Step Closer to Approval in Europe
Zolgensma is a gene therapy developed by AveXis for the treatment of spinal muscular atrophy. It was approved by the FDA in May of 2019, and was later cleared for…